Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al.

Other

Abstract:

Palabras claves:

Autores:

Anagnostis P., Ceausu I., Depypere H., Faustino R. Pérez-López, Goulis D.G., Lambrinoudaki I., Mintziori G., Mueck A., Paschou S.A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Trémollieres F.A.

Fuentes:

scopus